临床试验/NCT07255001

NCT07255001招募中不适用

Monitoring Physical Function Changes for Patients Living With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival

British Columbia Cancer Agency3 个研究点分布在 1 个国家目标入组 50 人开始时间: 2026年8月13日最近更新: 2026年9月15日

干预措施

试验速览

阶段: 不适用
状态: 招募中
发起方: British Columbia Cancer Agency
入组人数: 50
试验地点: 3
主要终点: Frequency of Participants with Hand Grip Strength (HGS) Measurements at 6 Months From Treatment Start Date

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are:

Is it feasible to measure hand grip strength as part of a clinic visit?
Are changes in hand grip strength related to changes in body composition?
Is hand grip strength related to a person's well-being?
Is hand grip strength related to how a tumour responds to treatment?

Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Basic Science
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age 18 years or older.
•Histological and/or radiological diagnosis of resectable, non-resectable, or metastatic PDAC. For resectable PDAC, adjuvant setting only.
•ECOG performance status 0-
•Life expectancy greater than 6 months as judged by the investigator.
•Planned for treatment, either as part of routine care or in combination with an investigational agent within another study.
•Ability to hold a dynamometer with one hand.

排除标准

•Individuals with CT imaging performed outside of Vancouver, BC, Canada.
•Individuals who are unfit to undergo CT imaging of the third lumbar vertebra (L3).
•Individuals who are currently participating in a structured moderate intensity resistance training program.
•Individuals who are otherwise judged by the investigator to be unfit to proceed with this protocol.
•Unable to comply with study assessments and follow-up.

研究组 & 干预措施

Main Study Arm

Experimental

The study arm all participants are enrolled into. Participants will complete hand grip strength assessments and questionnaires.

干预措施: Hand grip strength assessments using a dynamometer (Device)

结局指标

主要结局

Frequency of Participants with Hand Grip Strength (HGS) Measurements at 6 Months From Treatment Start Date

时间窗: From the date anti-cancer therapy is initiated until the 6-month follow-up assessment.

The percentage of participants with hand grip strength (HGS) test results at 6 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer.

Frequency of Participants with Hand Grip Strength (HGS) Measurements at 6 Months From Treatment Start Date

时间窗: From the date anti-cancer therapy is initiated until the 6-month follow-up assessment.

The percentage of participants with hand grip strength (HGS) test results at 6 months from treatment start date. Hand grip strength is measured in kilograms with a hand-held dynamometer.

次要结局

Frequency of Participants with Hand Grip Strength (HGS) Measurements at Study Baseline(At the time of the baseline assessment for the study.)
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 3 Months From Treatment Start Date(From the date anti-cancer therapy is initiated until the 3-month follow-up assessment.)
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 9 Months From Treatment Start Date(From the date anti-cancer therapy is initiated until the 9-month follow-up assessment.)
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 12 Months From Treatment Start Date(From the date anti-cancer therapy is initiated until the 12-month follow-up assessment.)
Proportion of Participants with Sarcopenia Using CT Image Alone (Sarcopenia CT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Proportion of Participants with Sarcopenia Using Physical Function Alone (Sarcopenia P)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Proportion of Participants with Sarcopenia Using a Combination of CT Image and Physical Function (Sarcopenia COMB)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Progression-Free Survival (PFS)(From the date anti-cancer therapy is initiated until the date of clinical progression, withdrawal, date of death, or end of study, whichever comes first, assessed up to 26 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Overall Survival (OS)(From the date anti-cancer therapy is initiated until the date of death or end of study, whichever comes first, assessed up to 26 months.)
Difference in Hand Grip Strength (HGS) Between Treatment Regimens(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Stage(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Grade(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Frequency of Participants with Hand Grip Strength (HGS) Measurements at Study Baseline(At the time of the baseline assessment for the study.)
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 3 Months From Treatment Start Date(From the date anti-cancer therapy is initiated until the 3-month follow-up assessment.)
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 9 Months From Treatment Start Date(From the date anti-cancer therapy is initiated until the 9-month follow-up assessment.)
Frequency of Participants with Hand Grip Strength (HGS) Measurements at 12 Months From Treatment Start Date(From the date anti-cancer therapy is initiated until the 12-month follow-up assessment.)
Proportion of Participants with Sarcopenia Using CT Image Alone (Sarcopenia CT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Proportion of Participants with Sarcopenia Using Physical Function Alone (Sarcopenia P)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Proportion of Participants with Sarcopenia Using a Combination of CT Image and Physical Function (Sarcopenia COMB)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Progression-Free Survival (PFS)(From the date anti-cancer therapy is initiated until the date of clinical progression, withdrawal, date of death, or end of study, whichever comes first, assessed up to 26 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Overall Survival (OS)(From the date anti-cancer therapy is initiated until the date of death or end of study, whichever comes first, assessed up to 26 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Objective Response Rate (ORR)(From the date of the baseline assessment scan until the date of clinical progression, withdrawal, date of death, or end of study, whichever comes first, assessed up to 26 months.)
Difference in Hand Grip Strength (HGS) Between Treatment Regimens(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Stage(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Hand Grip Strength (HGS) and Tumour Grade(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Difference in Hand Grip Strength (HGS) Between Sites of Metastasis(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Hand Grip Strength (HGS)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Index (SMI)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Density (SMD)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Skeletal Muscle Gauge (SMG)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Visceral Adipose Tissue (VAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Subcutaneous Adipose Tissue (SAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Global Health Status (QoL, per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Role Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Emotional Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Cognitive Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Social Functioning (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Fatigue (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Nausea and Vomiting (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Pain (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dyspnoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Insomnia (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Appetite Loss (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Constipation (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Diarrhoea (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Financial Difficulties (per EORTC QLQ-C30) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Food Aversion (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating and Weight Loss Worry (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Eating Difficulties (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Loss of Control (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Physical Decline (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Dry Mouth (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Indigestion/Heartburn (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Forcing Self to Eat (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Inadequate Information (per EORTC QLQ-CAX24) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Index Value (per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)
Strength and Direction of the Relationship Between Health Status (EQ-VAS per EuroQol EQ-5D-5L) and Intermuscular Adipose Tissue (IMAT)(From the date anti-cancer therapy is initiated until the follow-up assessments at 3, 6, 9, and 12 months.)

研究者

发起方

British Columbia Cancer Agency

申办方类型

Other

责任方

Sponsor

研究点 (3)

Loading locations...

相似试验

已完成

3 期

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor NeuropathyMultifocal Motor Neuropathy

NCT00666263Baxalta now part of Shire50

招募中

不适用

Assessment of Hand Grip Strength Using Jamar DynamometerType2diabetes

NCT05939908Diabetes Foundation, India5,000

撤回

不适用

Age-independent Decline in Manual Dexterity of Middle-aged and Older AdultsAging

NCT03803566University of Colorado, Boulder

尚未招募

不适用

To Assess hand grip strength in patients with type 2 diabetes

CTRI/2023/06/054475NA100

终止

不适用

Studying Changes in Physical Function Measures in Stem Cell Transplant Patients at Risk for Steroid MyopathyAcute Graft Versus Host Disease

NCT04521777M.D. Anderson Cancer Center24